121 results about "Ofloxacino" patented technology

The invention provides a composite degradable antibacterial artificial cerebral dura mater, comprising a vancomycin or ofloxacin hydrochloride injection, chitosan and sodium beta-glycerophosphate. The invention is characterized in that a spongy collagen biomembrane stent is prepared from a decellularized membrane-like derivative material, a chitosan solution with a concentration of 2% (w / v) and a sodium beta-glycerophosphate solution with a concentration of 56% (w / v) are used and mixed, and since a hydrogel formed by a compound of the chitosan solution and the sodium beta-glycerophosphate solution at a temperature of 37 DEG C has the characteristic of temperature sensitivity, the vancomycin or ofloxacin hydrochloride injection is added into the compound to form a solution which is used for soaking of the prepared spongy collagen biomembrane stent to prepare a suture-free cerebral dura mater, and the hydrogel compound uniformly infiltrates into the spongy collagen biomembrane stent after disposition in an incubator with a temperature of 37 DEG C for 10 min so as to form the absorbable artificial cerebral dura mater with antibacterial activity. The invention further provides a preparation method. The preparation method has the characteristics of convenience in preparation, easy film formation, low cost, convenient operation, etc.

The invention provides a preparation method for levofloxacin-N-oxide and relates to the field of a levofloxacin medicament. The preparation method comprises the following steps of: mixing the levofloxacin and 0.1mol / L hydrochloric acid solution according to a proportion of 0.03mol: 500ml, and dissolving the mixture at the temperature of between 80 and 100 DEG C; adding 100ml of hydrogen peroxide solution having the mass concentration of 30 percent by three times at the temperature of between 60 and 80 DEG C; reacting for 3 to 5 hours each time to obtain reaction solution; drying the reaction solution through distillation; and recrystallizing the residual water. The selection of the raw materials is convenient for the subsequential separating operation; by adding the hydrogen peroxide solution in steps, the progress of the reaction is controlled, the generation of byproducts is reduced, the conversion rate of the levofloxacin-N-oxide is improved and the generation of impurities is reduced; and by the method, the condition is easy to control, the route is simple, the solvent is obtained easily, the yield is 88.7 percent, the cost of the levofloxacin-N-oxide serving as a contrast is reduced greatly, and the product purity is high and over 99.5 percent, so the levofloxacin-N-oxide can be used as a working contrast.

The invention provides a process for preparing levofloxacin hemihydrate, comprising:(A) dissolving levofloxacin in a solvent selected from the group consisting of acetonitrile, acetonitrile:H2O, dimethyl sulfoxide, dimethyl sulfoxide:H2O, methyl ethyl ketone, methyl ethyl ketone:H2O, butanol, butanol:H2O, and mixtures thereof at an elevated temperature; and(B) crystallizing levofloxacin hemihydrate.

It is intended to provide a method of accurately and simply detecting a compound represented by the formula (I) in a human sample. For producing an antibody which recognizes a compound represented by the formula (I) and shows no cross-reaction with metabolites thereof, an N-oxide form of the compound represented by the formula (I) and desmethyl-levofloxacin, an antigen obtained by attaching bovine serum albumin to the carboxy group at position 6 of the compound represented by the formula (I) was used. Further, for constructing an immunoassay method for measuring the unmetabolized compound represented by the formula (I), the antibody was used.

The invention discloses a preparation method of levofloxacin-N-oxide. In the existing preparation method, a large number of reaction impurities exist, purification cannot be carried out easily, the consumption of hydrogen peroxide in reaction is large, and the subsequent treatment is troublesome. The preparation method comprises the following steps of: mixing levofloxacin and a solvent glacial acetic acid, and stirring the mixture at 60-70 DEG C until dissolution; adding catalyst which can be phosphotungstic acid, phosphomolybdic acid or sodium tungstate; adding hydrogen peroxide solution with the mass concentration of 25-35 percent in batches, and making the mixture react for 2-4 hours after each batch is added, and adding the hydrogen peroxide solution until the reaction is fully completed; carrying out vacuum distillation on reaction solution prepared via the reaction until the volume of the solution is one third of the original volume, adding an appropriate amount of water, then carrying out vacuum distillation on reaction solution again until the volume of the solution is one third of the original volume, repeating the vacuum distillation twice to three times, and drying via evaporation; and carrying out vacuum distillation on the prepared residues, adding a recrystallization solvent for recrystallization to obtain the levofloxacin-N-oxide. The invention has the advantages of fewer side actions, higher product purity, low consumption of the hydrogen peroxide, and convenient subsequent treatment.

The invention relates to a Bi / beta-Bi2O3 heterojunction material as well as a sodium gluconate-assisted synthesis method and application thereof, wherein the method comprises the steps: firstly, dissolving sodium gluconate in water, then adding a PEG4000 aqueous solution, adding a Bi(NO3)3 aqueous solution, mixing with formamide, and preparing a precursor material through a hydrothermal method; and further carrying out heat treatment in a nitrogen atmosphere to obtain the Bi / beta-Bi2O3 photocatalyst material. The Bi / beta-Bi2O3 heterojunction prepared by the preparation method disclosed by the invention is of a nest-shaped graded micro-nano structure and has excellent photocatalytic performance; and the Bi / beta-Bi2O3 heterojunction material has high photocatalytic degradation activity on rhodamine B and levofloxacin hydrochloride, and still has a high degradation rate after a cyclic photocatalytic reaction.

The invention particularly provides a kit and a method for detecting antituberculous drugs and metabolites thereof in a sample. The kit is used for detecting antituberculous drugs and metabolites thereof in a sample, and comprises a calibration product, a quality control product, an instrument quality control product and an isotope internal standard product, both the calibration material and the quality control material contain rifampicin, isoniazide, rifapentine, pyrazinamide, ethambutol, clofazimine, cycloserine, moxifloxacin, levofloxacin, linezolid, acetyl isoniazide, bedaquiline and deacetylrifampicin; the instrument quality control product comprises a methanol solution containing rifampicin, isoniazid, rifapentine, pyrazinamide, ethambutol, clofazimine, cycloserine, moxifloxacin, levofloxacin, linezolid, acetyl isoniazid, bedaquiline and deacetylrifampicin; the isotope internal standard substance contains an internal standard substance corresponding to a substance contained in the calibrator. The kit disclosed by the invention can be used for detecting the concentrations of the antituberculous drugs and metabolites thereof in various sample types.

The invention discloses an application of a substance for detecting an HLA-A*30:01 allele in evaluating the risk of human severe drug rash caused by levofloxacin. The invention also discloses an application of the substance for detecting the HLA-A*30:01 allele in preparation of a product for detecting or evaluating the risk of human adverse drug reaction responding to the levofloxacin. Experimentsprove that the human leukocyte antigen gene-HLA-A*30:01 allele is related to the risk of the severe drug rash caused by the levofloxacin. The HLA-A*30:01 allele can be used as a marker gene for predicting the occurrence risk of the severe drug rash caused by the levofloxacin.